FDA Approves UPTRAVI — Actelion Pharmaceuticals US, Inc.
Actelion Pharmaceuticals US, Inc. secured FDA approval for the intravenous administration of UPTRAVI (selexipag) under NDA 214275 on July 29, 2021, a regulatory milestone expected to diversify the company's market offerings within the respiratory therapeutic space.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day